{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["DFF332"],["DFF332","everolimus"],["DFF332","spartalizumab","taminadenant"]],"indication":"advanced/relapsed ccRCC and malignancies with HIF2α stabilizing mutations","name":"CDFF332A12101","nct_id":"NCT04895748","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cdff332a12101-nct04895748. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"DFF332 Single Agent","label":"Arm 1 Dose Escalation DFF332","type":"EXPERIMENTAL"},{"description":"Combination treatment DFF332 + Everolimus. This arm did not open.","label":"Arm 2 Dose Escalation DFF332 + Everolimus","type":"EXPERIMENTAL"},{"description":"Combination treatment DFF332 + Spartalizumab + Taminadenant. This arm did not open.","label":"Arm 3 Dose Escalation DFF332 + Spartalizumab + Taminadenant","type":"EXPERIMENTAL"},{"description":"DFF332 Single Agent in patients with ccRCC (age 18 years old and above). This arm did not open.","label":"Arm 1a Dose Expansion DFF332 in ccRCC","type":"EXPERIMENTAL"},{"description":"DFF332 Single Agent in patients with HIF stabilizing malignancies (age 12 years old and above). This arm did not open.","label":"Arm 1b Dose Expansion DFF332 in HIF stabilizing malignancies","type":"EXPERIMENTAL"},{"description":"Combination treatment DFF332 + Everolimus in patients with ccRCC (age 18 years old and above). This arm did not open.","label":"Arm 2a Dose Expansion DFF332 + Everolimus in ccRCC","type":"EXPERIMENTAL"},{"description":"Combination treatment DFF332 + Spartalizumab + Taminadenant in patients with ccRCC (age 18 years old and above). This arm did not open.","label":"Arm 3a Dose Expansion DFF332 + Spartalizumab + Taminadenant in ccRCC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-02-13","type":"ACTUAL"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":40,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"DFF332","otherNames":[],"type":"DRUG"},{"name":"RAD001","otherNames":["Everolimus"],"type":"DRUG"},{"name":"PDR001","otherNames":["Spartalizumab"],"type":"DRUG"},{"name":"NIR178","otherNames":["Taminadenant"],"type":"DRUG"}],"last_update":"2026-03-03","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2026-02-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)","timeFrame":"3 years"},{"measure":"Number of participants with dose interruptions and dose reductions","timeFrame":"3 years"},{"measure":"Dose intensity for DFF332 for dose escalation and expansion","timeFrame":"3 years"},{"measure":"Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 days) for DFF332 as a single agent and in combinations","timeFrame":"28 days"}],"references":[],"start_date":{"date":"2021-11-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies","url":"https://clinicaltrials.gov/study/NCT04895748"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cdff332a12101-nct04895748"}